Skip to main navigation
  • Contact Us
Xen 01
  • About Us
    • Management
    • Partnering
    • Board of Directors
  • Pipeline
    • Vudalimab (PD-1 x CTLA-4)
    • Plamotamab (CD20 x CD3)
    • XmAb104 (PD-1 x ICOS)
    • XmAb564 (IL-2-Fc)
    • XmAb819 (ENPP3 x CD3)
  • Technology
    • Bispecific Fc Domains
    • Cytotoxic Fc Domains
    • Immune Inhibitor Fc Domains
    • Xtend Fc Domains
    • Publications
  • Clinical Trials
    • Expanded Access Policy
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Corporate Responsibility
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Analyst Coverage
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
    • Contact Us
    • Email Alerts
  • Careers
    • Opportunities

You are here:
Home / Investors / 8-K

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Corporate Responsibility
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Email Alerts

Tools

Shareholder Tools

  • Snaphot
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

SEC Filing Details

Document Details

Form
8-K
Filing Date
Jul 6, 2021
Document Date
Jun 30, 2021
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Xencor, Inc.
Issuer
Xencor Inc

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.LAB - EX-101.LAB
EX-101.PRE - EX-101.PRE
XML - XBRL INSTANCE DOCUMENT
Xencor © Copyright 2023 | Privacy Policy
Scroll to top